• Publications
  • Influence
Symptom prevalence in the last week of life.
Palliative care is the management of patients with progressive, far-advanced disease for whom the prognosis is limited and the focus of care is quality of life. During the last days of life, it isExpand
  • 174
  • 4
  • PDF
Treatment of keloids by high-dose-rate brachytherapy: A seven-year study.
PURPOSE To analyze the results obtained in a prospective group of patients with keloid scars treated by high-dose-rate (HDR) brachytherapy with or without surgery. METHODS AND MATERIALS One hundredExpand
  • 135
  • 3
  • PDF
Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain.
BACKGROUND To assess management patterns and outcome in patients with glioblastoma multiforme (GBM) treated during 2008-2010 in Spain. METHODS Retrospective analysis of clinical, therapeutic, andExpand
  • 59
  • 3
  • PDF
Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment.
PURPOSE Nonmelanoma skin cancer (NMSC) is the commonest cancer in humans. NMSC treatment currently includes surgery, radiation therapy, and topical approaches. The objective was to analyze andExpand
  • 24
  • 3
Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity
PurposeTo evaluate efficacy and toxicity after salvage brachytherapy (BT) in prostate local recurrence after radiation therapy.Methods and materialsBetween 1993 and 2007, we retrospectively analyzedExpand
  • 44
  • 2
  • PDF
Exeresis and brachytherapy as salvage treatment for local recurrence after conservative treatment for breast cancer: results of a ten-year pilot study.
PURPOSE To analyze the long-term results of a pilot study assessing excision and brachytherapy as salvage treatment for local recurrence after conservative treatment of breast cancer. METHODS ANDExpand
  • 60
  • 2
Cosmetic outcome of breast conservative treatment for early stage breast cancer
PurposeTo evaluate the cosmetic outcome of breast conservative therapy and to examine the degree of agreement between the patients’ and oncologists’ ratings. We also analyze the influence of severalExpand
  • 27
  • 2
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
We sought to determine the impact of bevacizumab on reduction of tumor size prior to chemoradiotherapy in unresected glioblastoma patients. Patients were randomized 1:1 to receive temozolomide (TMZExpand
  • 22
  • 1
Dose escalation with high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk prostate cancer:
82 Background: To report early and late toxicity and preliminary biochemical outcome in in a prospective serie of 445 patients with intermediate- or high-risk clinically localized prostate cancerExpand
  • 2
  • 1
...
1
2
3
4
5
...